medigraphic.com
ISSN 0016-3813 (Print)

2007, Number 1

<< Back Next >>

Gac Med Mex 2007; 143 (1)

III. Diseño, síntesis y estudio de un compuesto con posible actividad tripanosomicida

Aguirre-Alvarado C, Fabiola Zaragoza-Martínez, Rodríguez-Páez L, Nogueda-Torres B, Baeza-Ramírez I, Wong-Ramírez C

Language: Spanish
References: 18
Page: 39-43
PDF size: 122.30 Kb.


ABSTRACT

During the symposium “Design of new drugs in Mexico”, we presented a summary of the research that led us to develop substances with trypanocidal activity. The epidemiological pattern of Chagas’ disease was briefly described as well as the factor that explains the low cure rate seen among chagasic patients.
The strategy used to develop a new compound with trypanocidal activity was the following: we used T. cruzi a-hydroxiacid dehydrogenase isoenzyme II, as a target enzyme, trying to inhibit the energetic methabolism of this parasite. N-isopropyl oxamic acid the substance we designed was synthesized and its biological activity was determined. It is a selective inhibitor of this enzyme and in addition, showed trypanocidal activity on cultured epimastigotes, circulating trypomastigotes and intracellular amastigotes. Preliminary studies show the trypanocidal effect of the ethyl ester of N-isopropyl oxamic acid on intracellular amastigotes. This compound reduced by 60-80% the number of amastigotes nests on both cardiac and skeletal muscle, whereas Nifurtimox, the currently drug used for treatment of this disease, produced a reduction on amastigotes nests of 20-30%, in agreement with previous reports describing the low trypanocidal effect of this compound, in chronic stages of Chagas’ disease


REFERENCES

  1. World Health Organization. Chagas disease special program for research and training in tropical diseases. 1993, pp 67-75.

  2. World Health Organization. Control of Chagas disease. Tech Rep Ser. 2002;905:1-109.

  3. Urbina JA. Parasitological cure of Chagas disease: is it possible? Is it relevant? Mem Inst Oswaldo Cruz 1999;94:349-355.

  4. Coura RJ, De Castro S. A critical review on Chagas disease. Chemotherapy 2002;97:3-24.

  5. Opperdoes FR. Biochemical peculiarities of trypanosomes, African and South American. Br Med Bull 1985;41:130-136.

  6. Bakker BM, Westerhoff HV, Opperdoes FR, Michels PAM. Methabolic control analysis of glycolysis in trypanosomes as an approach to improve selectivity and effectiveness of drugs. Mol Biochem Pharmacol 2000;106:1-10.

  7. Verlinde CL, Hannaert V, Blonski C, WiIIson M, Perie JJ, Fothergill-Gilmore lA, et al. Glycolysis as a target for the design of new antitrypanosome drugs. Drug Resist Update 2001;41:130-136.

  8. Coronel CE, Roval LE, Gerez-de Burgos NM, Burgos C, Blanco A. Properties of a-hydroxyacid dehydrogenase isozymes from Trypanosoma cruzi. Mol Biochem Parasitol 1981;4:29-38.

  9. Coronel C, Gerez-de Burgos NM, Burdos C, Blanco A. Separación y propiedades catalíticas de las izo enzimas de la a-hidroxiácido deshidrogenasa de Tripanosoma cruzi. Medicina (Buenos Aires) 1980; 40:159-164.

  10. Montamat EE, Arauso SS, Blanco A. Subcellular localization of leucine aminotransferase and a-hydroxiacid dehydrogenase in Trypanosoma cruzi. Mol Biochem Parasitol 1987;22:185-93.

  11. Gerez de Burgos NM, Burgos C, Montamat EE, Rovai LE, Blanco A. Inhibition by gossypol of oxidoreductases from Trypanosoma cruzi. Biochem Pharmacol 1984;33:955-959.

  12. Elizondo S, Chena MA, Rodríguez-Paez L, Nogueda B, Baeza I, Wong C. Inhibition of Trypanosoma cruzi a-hydroxyacid dehydrogenase isozyme II by N-isopropyl oxamate and its effect on intact epimastigotes. J Enz Inhib Med Chem 2003;18:265-271.

  13. Adunate J, Repeto V, Letelier M, Morillo A. The carboxyl esterases of Trypanosome cruzi epimastigotes. Comp Biochem Physiol 1987;86:67-71.

  14. Chena M, Elizondo S, Rodríguez-Páez L, Nogueda B, Baeza I, Wong C. Trypanocidal activity of N-isopropyl oxamate on culture epimastigotes and murine trypanosomiasis using different Trypanosoma cruzi strains. J Enz Inhib Med Chem 2005;20:189-197.

  15. Zaragoza M. Efecto tripanosomicida de tres ésteres etílicos de oxamatos N-substituidos, sobre estadios de Trypanosoma cruzi, presentes en huésped vertebrado. Tesis de Maestría ENCB-IPN, 2005.

  16. Nogueda B. Desarrollo de inhibidores de oxidorreductasas de T. cruzi con posible actividad tripanosomicida. Tesis Doctoral ENCB-IPN, 1995.

  17. Elizondo S. Estudio de inhibidores de la alfa hidroxiácido deshidrogenada de Tyipanosoma cruzi con posible actividad tripanosomicida. Tesis de Maestría ENCB-IPN, 1999.

  18. Filardi L. Brener Z. Rapid method for testing in vivo the susceptibility of different strains of Trypanosoma cruzi to active




2020     |     www.medigraphic.com